Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Revlimid lenalidomide regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Revlimid lenalidomide from Celgene to treat patients with transfusion-dependent anemia

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE